首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Prognostic utility of biochemical markers of cardiovascular risk: Impact of biological variability
【24h】

Prognostic utility of biochemical markers of cardiovascular risk: Impact of biological variability

机译:心血管风险的生化标志物的预后效用:生物变异性的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Although a variety of biochemical markers are used to help predict the risk of cardiovascular disease, the prognostic utility of any marker used as a risk assessment tool is dependent on the long- and short-term biological variability that the marker shows in different individuals. Methods: We measured total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol; triglycerides; high-sensitivity C-reactive protein (hsCRP); total fibrinogen; and γ? fibrinogen in blood samples collected from 15 apparently healthy individuals over the course of 1 year. Repeated measures variation estimates were used to calculate short- and long-term intraclass correlation coefficients (ICC), within- and between-subject coefficients of variation (CVI and CVG, respectively), validity coefficients, and indices of individuality for each marker. Results: HDL cholesterol demonstrated the lowest variability profile, with an ICC of 0.84 and CVI of 11.1 (95% CI: 8.3, 17.0). hsCRP showed the highest levels of short- and long-term within-subject variability [CVI (95% CI): 54.8 (32.8, 196.3) and 77.1 (53.3, 141.3), respectively]. Stated differently, it would require five separate measurements of hsCRP, performed on samples collected over multiple days, to provide the risk assessment information provided by a single measurement of HDL cholesterol. γ? Fibrinogen demonstrated an ICC of 0.79 and CVI of 14.3 (95% CI: 10.6, 21.9). Conclusions: hsCRP showed very high biological variability, such that a single measurement of hsCRP lacks sufficient clinical utility to justify routine measurement. The variability profile of γ? fibrinogen was not markedly different than HDL cholesterol, necessitating only a limited number of measurements to establish an individual's risk of cardiovascular disease.
机译:背景:尽管使用了多种生物化学标记物来帮助预测心血管疾病的风险,但是用作风险评估工具的任何标记物的预后效用取决于标记物在不同个体中表现出的长期和短期生物学变异性。方法:我们测量了总,低密度脂蛋白(LDL)和高密度脂蛋白(HDL)胆固醇;甘油三酸酯高敏C反应蛋白(hsCRP);总纤维蛋白原和γ?在1年的时间里,从15名貌似健康的人身上采集的血液样本中的纤维蛋白原。重复测量变异估计用于计算短期和长期组内相关系数(ICC),受试者内部和受试者之间的变异系数(分别为CVI和CVG),有效性系数和每个标记的个性指数。结果:HDL胆固醇表现出最低的变异性,ICC为0.84,CVI为11.1(95%CI:8.3,17.0)。 hsCRP显示最高水平的短期和长期受试者内部变异性[CVI(95%CI):分别为54.8(32.8,196.3)和77.1(53.3,141.3)]。换句话说,它将需要对多天收集的样本进行五次单独的hsCRP测量,以提供由一次HDL胆固醇测量提供的风险评估信息。 γ?纤维蛋白原的ICC为0.79,CVI为14.3(95%CI:10.6,21.9)。结论:hsCRP具有很高的生物学变异性,因此单次测量hsCRP缺乏足够的临床实用性来证明常规测量的合理性。 γ?的变异性纤维蛋白原与HDL胆固醇没有显着差异,仅需进行少量测量即可确定个人患心血管疾病的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号